An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSD

Completed · Phase 2

Conditions studied: Post Traumatic Stress Disorder

In brief

This is an extension study of participants who previously completed a Transcend-sponsored clinical trial evaluating TSND-201 as a treatment for PTSD. Participants will be followed for up to 52 weeks. During the 52 week period, PTSD symptoms and safety will be assessed monthly. Participants' PTSD symptoms will be assessed at each observational visit and if criteria for Relapse has been met, participants may be eligible to receive a course of TSND-201 treatment.

Key facts

Study ID
NCT06237426
Run by
Transcend Therapeutics
People needed
44
Starts
2024-03-06
Expected to finish
2025-10-06
Last updated by the study team
2025-11-25

Who can join

Age: 18 and older, up to 71. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.